Last price update: 24 Apr 24 23:00 GMT
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Two investing influencers have expressed opposite takes on how investors should play the current market. Michael Burry, of The Big Short fame, is no stranger to issuing ominous warnings for investors.
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive.
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.
Zug, switzerland and cambridge, mass., jan. 11, 2023 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in b. riley securities' 3 rd annual oncology conference on wednesday, january 18, 2023, at 10 30 a. m. et.
Zug, switzerland and boston, dec. 19, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced the appointment of alex harding, m. d., m. b. a., as senior vice president and head of business development, effective january 5, 2023. dr. harding brings extensive leadership experience in biopharma business development and corporate strategy and joins crispr therapeutics to lead the company' s business development operations.
Zug, switzerland and boston, nov. 10, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today presented data for ctx130 for the treatment of relapsed or refractory renal cell carcinoma ( rcc) as an oral presentation delivered by city of hope' s sumanta pal, m. d. additionally, together with collaborators at the moffitt cancer center, the company presented preclinical data in a poster presentation demonstrating the potential of potency enhanced anti cd83 car t cells in preventing relapse in acute myeloid leukemia ( aml).
Zug, switzerland and boston, nov. 03, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that it will present a poster on ctx110 , its wholly owned allogeneic car t cell investigational therapy targeting cd19 b cell malignancies, at the american society of hematology ( ash) 2022 annual meeting, taking place DEC ember 10 13, 2022, virtually and at the ernest n. morial convention center in new orleans, louisiana.
Exagamglogene autotemcel ( exa cel), formerly known as ctx001 submission to the u. s. food and drug administration ( fda) for rolling review expected to begin in november, with completion of the u. s. submission package expected in q1 2023; ema and mhra submissions are on track for q4 2022
Zug, switzerland and boston, oct. 27, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that its chief operating officer, lawrence klein, ph. d., will be stepping down from the company to pursue external opportunities. it is expected that he will remain with the company through year end to help ensure a smooth transition. a search is underway to find a successor to dr. klein.
Zug, switzerland and boston, sept. 28, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that the u. s. food and drug administration ( fda) granted regenerative medicine advanced therapy ( rmat) DES ignation to ctx130 , the company' s wholly owned allogeneic car t cell therapy targeting cd70, for the treatment of mycosis fungoides and sézary SYN drome ( mf ss).
Boston & zug, switzerland ( business wire) vertex pharmaceuticals incorporated ( nasdaq vrtx) and crispr therapeutics ( nasdaq crsp) today announced that vertex has concluded discussions with the u. s. food and drug administration ( fda), and the fda granted exagamglogene autotemcel ( exa cel) a rolling review for the potential treatment of sickle cell disease ( scd) and transfusion dependent beta thalassemia ( tdt). vertex will submit its biologics licensing application ( bla) for exa cel for rolli
CLI mb 111 and CLI mb 121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel ( exa cel), formerly known as ctx001 , with the european medicines agency ( ema) and the medicines and healthcare products regulatory agency ( mhra); discussions with the u. s. food and drug administration ( fda) ongoing
